Track topics on Twitter Track topics that are important to you
Dynavax Technologies announced that the FDA has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the U.S. in more than 25 years and the only two-dose hepatitis […]
The post FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B prevention appeared first on CenterWatch News Online.
Original Article: FDA approves Dynavax’s HEPLISAV-B for adult hepatitis B preventionNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...